The pharmacokinetics of thiabendazole and its metabolites in an anephric patient undergoing hemodialysis and hemoperfusion.
The pharmacokinetics of thiabendazole and its metabolites were determined after the first dose and during hemodialysis and hemoperfusion in an anephric female patient treated for a strongyloides infection. The half-live, volume of distribution, and clearance for thiabendazole were 1.17 hour, 2.76 liters/kg, and 27.2 ml/min . kg, respectively. While thiabendazole and the 5-OH metabolite did not accumulate during multiple dosing, the glucuronide and sulfate esters accumulated extensively despite hemodialysis and hemoperfusion. Hemodialysis clearances for all compounds were poor. Hemoperfusion removal was much better but declined rapidly after the first hour. If rapid removal of thiabendazole and its metabolites is required, the hemoperfusion column should be changed hourly.
D000328:Adult; D005260:Female; D006084:Graft Rejection / Q000187:drug effects; D006207:Half-Life; D006400:Hematocrit; D006464:Hemoperfusion; D006801:Humans; D006900:Hydroxylation; D007668:Kidney / Q000502:physiology*; D016030:Kidney Transplantation; D007700:Kinetics; D006435:Renal Dialysis; D013322:Strongyloidiasis / Q000188:drug therapy; D013827:Thiabendazole / Q000378:metabolism*
D013827:Thiabendazole